IT1307864B1 - Metodo diagnostico per il riconoscimento di neoplasie umane attraversola determinazione dell'isoforma ctn-c della tn-c, frammenti di - Google Patents

Metodo diagnostico per il riconoscimento di neoplasie umane attraversola determinazione dell'isoforma ctn-c della tn-c, frammenti di

Info

Publication number
IT1307864B1
IT1307864B1 IT1999FI000094A ITFI990094A IT1307864B1 IT 1307864 B1 IT1307864 B1 IT 1307864B1 IT 1999FI000094 A IT1999FI000094 A IT 1999FI000094A IT FI990094 A ITFI990094 A IT FI990094A IT 1307864 B1 IT1307864 B1 IT 1307864B1
Authority
IT
Italy
Prior art keywords
ctn
isoform
determination
fragments
recognition
Prior art date
Application number
IT1999FI000094A
Other languages
English (en)
Inventor
Luciano Zardi
Original Assignee
Istituto Naz Per La Ricerca Su
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Naz Per La Ricerca Su filed Critical Istituto Naz Per La Ricerca Su
Publication of ITFI990094A0 publication Critical patent/ITFI990094A0/it
Priority to IT1999FI000094A priority Critical patent/IT1307864B1/it
Priority to JP2000612753A priority patent/JP4577665B2/ja
Priority to AT00925224T priority patent/ATE277352T1/de
Priority to CA2370666A priority patent/CA2370666C/en
Priority to AU44015/00A priority patent/AU779015B2/en
Priority to EP00925224A priority patent/EP1173766B1/en
Priority to DE60014064T priority patent/DE60014064T2/de
Priority to US09/959,373 priority patent/US7109301B1/en
Priority to DK00925224T priority patent/DK1173766T3/da
Priority to PCT/EP2000/003550 priority patent/WO2000063699A1/en
Priority to ES00925224T priority patent/ES2226823T3/es
Publication of ITFI990094A1 publication Critical patent/ITFI990094A1/it
Application granted granted Critical
Publication of IT1307864B1 publication Critical patent/IT1307864B1/it

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IT1999FI000094A 1999-04-20 1999-04-20 Metodo diagnostico per il riconoscimento di neoplasie umane attraversola determinazione dell'isoforma ctn-c della tn-c, frammenti di IT1307864B1 (it)

Priority Applications (11)

Application Number Priority Date Filing Date Title
IT1999FI000094A IT1307864B1 (it) 1999-04-20 1999-04-20 Metodo diagnostico per il riconoscimento di neoplasie umane attraversola determinazione dell'isoforma ctn-c della tn-c, frammenti di
DE60014064T DE60014064T2 (de) 1999-04-20 2000-04-19 Einetenascin-c isoform als marker für neoplasmen
AT00925224T ATE277352T1 (de) 1999-04-20 2000-04-19 Einetenascin-c isoform als marker für neoplasmen
CA2370666A CA2370666C (en) 1999-04-20 2000-04-19 A tenascin-c isoform as a marker for neoplasias
AU44015/00A AU779015B2 (en) 1999-04-20 2000-04-19 A tenascin-C isoform as a marker for neoplasias
EP00925224A EP1173766B1 (en) 1999-04-20 2000-04-19 A tenascin-c isoform as a marker for neoplasias
JP2000612753A JP4577665B2 (ja) 1999-04-20 2000-04-19 腫瘍形成のマーカーとしてのテネイシン−ｃアイソフォーム
US09/959,373 US7109301B1 (en) 1999-04-20 2000-04-19 Tenascin-C isoform as marker for neoplasias
DK00925224T DK1173766T3 (da) 1999-04-20 2000-04-19 Isoform af tenascin-C som markör for neoplasier
PCT/EP2000/003550 WO2000063699A1 (en) 1999-04-20 2000-04-19 A tenascin-c isoform as a marker for neoplasias
ES00925224T ES2226823T3 (es) 1999-04-20 2000-04-19 Isoforma c de la tenascina como marcador de neoplasias.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999FI000094A IT1307864B1 (it) 1999-04-20 1999-04-20 Metodo diagnostico per il riconoscimento di neoplasie umane attraversola determinazione dell'isoforma ctn-c della tn-c, frammenti di

Publications (3)

Publication Number Publication Date
ITFI990094A0 ITFI990094A0 (it) 1999-04-20
ITFI990094A1 ITFI990094A1 (it) 2000-10-20
IT1307864B1 true IT1307864B1 (it) 2001-11-19

Family

ID=11352932

Family Applications (1)

Application Number Title Priority Date Filing Date
IT1999FI000094A IT1307864B1 (it) 1999-04-20 1999-04-20 Metodo diagnostico per il riconoscimento di neoplasie umane attraversola determinazione dell'isoforma ctn-c della tn-c, frammenti di

Country Status (11)

Country Link
US (1) US7109301B1 (it)
EP (1) EP1173766B1 (it)
JP (1) JP4577665B2 (it)
AT (1) ATE277352T1 (it)
AU (1) AU779015B2 (it)
CA (1) CA2370666C (it)
DE (1) DE60014064T2 (it)
DK (1) DK1173766T3 (it)
ES (1) ES2226823T3 (it)
IT (1) IT1307864B1 (it)
WO (1) WO2000063699A1 (it)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1317108B1 (it) * 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
EP1401870A4 (en) * 2001-05-24 2006-04-19 Human Genome Sciences ANTIBODIES AGAINST TUMOR NECROSIS FACTOR DELTA (APRIL)
MXPA04004658A (es) * 2001-11-19 2004-08-13 Applied Molecular Evolution Anticuerpos monoclonales especificos para tumores.
AU2005304031B2 (en) * 2004-11-09 2009-04-23 Philogen Spa Antibodies against tenascin-C
WO2009124150A2 (en) 2008-04-01 2009-10-08 Biosearch Technologies, Inc. Stabilized nucleic acid dark quencher-fluorophore probes
TW201209063A (en) 2010-08-13 2012-03-01 Roche Glycart Ag Anti-tenascin-C A2 antibodies and methods of use
EP3455254B1 (en) 2016-05-11 2021-07-07 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
CN109071640B (zh) * 2016-05-11 2022-10-18 豪夫迈·罗氏有限公司 经修饰抗生腱蛋白抗体及使用方法
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
EP3601346A1 (en) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
CN107058596A (zh) * 2017-06-19 2017-08-18 上海市第十人民医院 一种与恶性胶质瘤诊断相关的标志物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8547291A (en) * 1990-09-05 1992-03-30 Wistar Institute, The Monoclonal antibodies against tenascin
JPH0643167A (ja) * 1992-04-06 1994-02-18 Amano Pharmaceut Co Ltd 癌マーカーであるテネイシン及びその定量法
WO1996001653A1 (en) * 1994-07-11 1996-01-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US6482410B1 (en) * 1994-09-16 2002-11-19 The Scripps Research Institute Cytotactin derivatives that stimulate attachment and neurite outgrowth, and methods of making same
JP3850492B2 (ja) * 1996-08-23 2006-11-29 独立行政法人理化学研究所 テネイシン誘導因子

Also Published As

Publication number Publication date
ITFI990094A0 (it) 1999-04-20
EP1173766A1 (en) 2002-01-23
US7109301B1 (en) 2006-09-19
AU779015B2 (en) 2005-01-06
JP2002542486A (ja) 2002-12-10
ES2226823T3 (es) 2005-04-01
WO2000063699A1 (en) 2000-10-26
AU4401500A (en) 2000-11-02
EP1173766B1 (en) 2004-09-22
ITFI990094A1 (it) 2000-10-20
DK1173766T3 (da) 2005-01-31
CA2370666C (en) 2010-06-01
JP4577665B2 (ja) 2010-11-10
DE60014064T2 (de) 2006-02-23
CA2370666A1 (en) 2000-10-26
DE60014064D1 (de) 2004-10-28
ATE277352T1 (de) 2004-10-15

Similar Documents

Publication Publication Date Title
DE60220719D1 (de) Antikörper gegen das muc18-antigen
CY1112458T1 (el) Ενα αντισωμα ειδικο για διαλυτο baff για χρηση στην αντιμετωπιση του καρκινου
CY1110256T1 (el) Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
EP1467757A4 (en) USE OF ANTIBODIES TO THE MUC18 ANTIGEN
DE60134962D1 (de) Anti-ccr4 antikörper und fragmente davon
BRPI9912227B8 (pt) método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método.
ATE438719T1 (de) Spezifischer marker für prostatakrebs
ITMI20010562A1 (it) Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
ATE318147T1 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
IT1307864B1 (it) Metodo diagnostico per il riconoscimento di neoplasie umane attraversola determinazione dell'isoforma ctn-c della tn-c, frammenti di
MXPA04006517A (es) Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
DE50207866D1 (de) Verwendung löslicher cytokeratin-1-fragmente in diagnostik
DE60027905D1 (de) Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
AU2003225900A1 (en) Antibody disulfide isomers, use thereof, and methods of analyzing same
MXPA03009138A (es) Produccion de anticuerpos monoespecificos policlonales, contra variantes del receptor activador del plasminogeno de tipo uroquinasa (upar) del4, del5 y del4+5 y su uso para propositos de diagnostico y terapeutico.
AU4098201A (en) Method for diagnosing efficacy of xenotypic antibody therapy
DE60023460D1 (de) Cdna von menschlicher methylentetrahydrofolatreduktase
NO20022276L (no) Placental human neurokinin-B-forlöper
SE0202608D0 (sv) New sequences
ITBZ20020040A1 (it) Metodo per la identificazione attraverso la progettazione e l'uso di appositi microchip -dna microarray della trasformazione tumorale del tessuto prostatico, valutazione della sua malignita' e prognosi del cancro prostatico umano mediante un nuovo me
FR2832155B1 (fr) Anticorps stimulant la production d'il-1ra
ATE256682T1 (de) Sigma-2 rezeptoren als biomarkierer der tumorzellenproliferation
SI1461360T1 (sl) Konjugati, ki obsegajo protitelo, specifično za domeno ED-B fibronektina, in njihova uporaba za detekcijo in zdravljenje tumorjev